The Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-Structure Infections.
Arbeit, Robert D. 1,a; Maki, Dennis 2; Tally, Francis P. 1; Campanaro, Edward 1; Eisenstein, Barry I. 1; Daptomycin 98-01 and 99-01 Investigators
[Article] Clinical Infectious Diseases. 38(12):1673-1681, June 15, 2004.

(Format: HTML, PDF)

: Daptomycin is the first available agent from a new class of antibiotics, the cyclic lipopeptides, that has activity against a broad range of gram-positive pathogens, including organisms that are resistant to methicillin, vancomycin, and other currently available agents. Daptomycin (4 mg/kg intravenously [iv] every 24 h for 7-14 days) was compared with conventional antibiotics (penicillinase-resistant penicillins [4-12 g iv per day] or vancomycin [1 g iv every 12 h]) in 2 randomized, international trials involving 1092 patients with complicated skin and skin-structure infections. Among 902 clinically evaluable patients, clinical success rates were 83.4% and 84.2% for the daptomycin- and comparator-treated groups, respectively (95% confidence interval, -4.0 to 5.6). Among patients successfully treated with iv daptomycin, 63% required only 4-7 days of therapy, compared with 33% of comparator-treated patients (P < .0001). The frequency and distribution of adverse events were similar among both treatment groups. Overall, the safety and efficacy of daptomycin were comparable with conventional therapy.

(C) Copyright Oxford University Press 2004.